Should I buy or sell Orion Oyj stock right now?

1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Orion Oyj in the last twelve months. There are currently 1 hold rating for the stock. The consensus among Wall Street research analysts is that investors should "hold" ORINY shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in ORINY, but not buy additional shares or sell existing shares. View ORINY analyst ratings or view top-rated stocks .

How have ORINY shares performed in 2024?

Orion Oyj's stock was trading at $20.70 at the beginning of the year. Since then, ORINY stock has decreased by 13.0% and is now trading at $18.00. View the best growth stocks for 2024 here .

Are investors shorting Orion Oyj?

Orion Oyj saw a decrease in short interest in the month of March. As of March 15th, there was short interest totaling 100 shares, a decrease of 50.0% from the February 29th total of 200 shares. Based on an average trading volume of 200 shares, the short-interest ratio is currently 0.5 days. View Orion Oyj's Short Interest .

How were Orion Oyj's earnings last quarter?

Orion Oyj (OTCMKTS:ORINY) announced its quarterly earnings results on Tuesday, February, 13th. The company reported $0.29 earnings per share (EPS) for the quarter. The firm had revenue of $345.76 million for the quarter. Orion Oyj had a net margin of 18.21% and a trailing twelve-month return on equity of 27.75%.

Is Orion Oyj a good dividend stock?

Orion Oyj (OTCMKTS:ORINY) pays an annual dividend of $0.37 per share and currently has a dividend yield of 2.05%. The dividend payout ratio is 44.05%. This payout ratio is at a healthy, sustainable level, below 75%. Based on earnings estimates, ORINY will have a dividend payout ratio of 36.27% next year. This indicates that the company will be able to sustain or increase its dividend. Read our dividend analysis for ORINY .

How do I buy shares of Orion Oyj?

Shares of ORINY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

OTCMKTS:ORINY

Orion Oyj (ORINY) Stock Price, News & Analysis

→ Your Next Portfolio Star: Revealing 2024's Top Stock Pick (From Darwin) (Ad)

Free ORINY Stock Alerts

$18.00

0.00 (0.00%)

(As of 04/18/2024 ET)

Compare

Today's Range: $18.00
▼
$18.00
50-Day Range: $18.00
▼
$23.62
52-Week Range: $18.00
▼
$24.40

Volume: 19 shs
Average Volume: 52 shs
Market Capitalization: $5.08 billion

P/E Ratio: 21.43
Dividend Yield: 2.06%
Price Target: N/A

Stock Analysis Analyst Forecasts Chart Dividend Earnings Headlines Short Interest

Get Orion Oyj alerts:

Ad WealthPress

Chances are you know the firms on this list

These are the entities that can buy MILLIONS of shares in a single day… I’m talking about huge orders that literally move the share price 1%, 2%, even 5% or more in the process. Why am I showing you that list? Well, because if you have a way to successfully detect which stocks these elite traders are likely buying in real time… All you have to do is ride the coattails of their massive orders and you can target endless trading opportunities without leaving your money exposed to the markets for too long. And in case you didn’t already know…

That’s exactly how this expert trader plans to trade his #1 ticker for 2024

About Orion Oyj Stock (OTCMKTS:ORINY)

Orion Oyj develops, manufactures, and markets human and veterinary pharmaceuticals and active pharmaceutical ingredients (APIs) in Finland, Scandinavia, rest of Europe, North America, and internationally. The company provides prescription drugs and self-care products, which includes Nubeqa for the treatment of prostate cancer; Precedex, Dexdor, and Precedex for human use; Burana for inflammatory pain; Divina series for menopausal symptoms; Trexan for rheumatoid arthritis and cancer; Stalevo, Entacapone, and Comtess/Comtan for Parkinson's disease; Biosimilars for rheumatoid arthritis and inflammatory bowel diseases; and Simdax for acute decompensated heart failure, as well as Fareston for breast cancer. It also offers Salmeterol/fluticasone Easyhaler, Budesonide/formoterol Easyhaler, Formoterol Easyhaler, Budesonide Easyhaler, Beclomet Easyhaler, and Buventol Easyhaler drugs for the treatment of asthma and chronic obstructive pulmonary disease. In addition, the company provides veterinary drugs comprising Bonqat, Clevor, Domosedan, Domitor, Antisedan, Dexdomitor, Domosedan Gel, Sileo, and Tessie; APIs for generic compounds and proprietary products, as well as contract manufacturing services; and markets and sells veterinary drugs manufactured by other international companies. Further, the company has partnership with Propeller Health to connect the Easyhaler(R) product portfolio; and a research collaboration and license agreement with Amneal Pharmaceuticals, Inc. to commercialize Amneal's generic products. Orion Oyj was founded in 1917 and is headquartered in Espoo, Finland.

ORINY Stock Price History

30 days | 90 days | 365 days | Advanced Chart

ORINY Stock News Headlines

March 20, 2024 | msn.com

Orion Oyj goes ex dividend tomorrow

March 19, 2024 | seekingalpha.com

ORN Orion Group Holdings, Inc.

April 19, 2024 | InvestorPlace (Ad)

New crypto project uncovers 2,050% in 65 days

During the event on Tuesday, April 23 at 10 am ET, I’ll be giving away the name and ticker symbol of crypto that could surge in price. I believe it will be the best performing crypto of 2024.

March 4, 2024 | finance.yahoo.com

Orion Corporation: Managers’ transactions – Juhani Kankaanpää

February 26, 2024 | realmoney.thestreet.com

Orion Oyj just downgraded at Jefferies, here's why

February 22, 2024 | finance.yahoo.com

Orion and Save the Children Finland announce cooperation to promote well-being of children in Finland and globally

February 21, 2024 | investing.com

Orion Oyj B (ORNBV)

February 19, 2024 | finance.yahoo.com

Orion to investigate the possible outsourcing of its pharmaceutical production in Kuopio, Finland

April 19, 2024 | InvestorPlace (Ad)

New crypto project uncovers 2,050% in 65 days

During the event on Tuesday, April 23 at 10 am ET, I’ll be giving away the name and ticker symbol of crypto that could surge in price. I believe it will be the best performing crypto of 2024.

February 13, 2024 | finance.yahoo.com

Orion Group Financial Statement Release January–December 2023

February 7, 2024 | finance.yahoo.com

119,021 Orion Corporation A shares converted into B shares

January 29, 2024 | finance.yahoo.com

Orion Corporation and Newel Health enter into licensing agreement for a digital therapeutic (DTx) ODD-403 (“Rohkea”) in pain

January 29, 2024 | finance.yahoo.com

Orion publishes Financial Statement Release for 2023 and holds a webcast on 13 February 2024

January 27, 2024 | finance.yahoo.com

Additional ODM-208/MK-5684 Phase II data presented at ASCO-GU 2024

January 11, 2024 | finance.yahoo.com

Insurance portfolio of Orion Pension Fund’s B fund transferred to an external pension insurance company – the transfer has approximately EUR 31 million positive impact on Orion’s result in 2023

January 11, 2024 | finance.yahoo.com

Recommendation by the Orion Nomination Committee on the proposals to be submitted to the 2024 Annual General Meeting

January 8, 2024 | msn.com

Orion collaborates with Glykos to develop next-generation ADCs

January 8, 2024 | finance.yahoo.com

Orion and Glykos announce research collaboration and licensing agreement to develop next-generation ADCs

January 8, 2024 | finance.yahoo.com

Orion Corporation: Managers’ transactions – Ari Lehtoranta

January 6, 2024 | morningstar.com

Orion Oyj ADR ORINY

January 5, 2024 | finance.yahoo.com

Orion and MSD Announce Initiation of Two Phase 3 Trials Evaluating ODM-208/MK5684 in Certain Patients with Metastatic Castration-Resistant Prostate Cancer

December 27, 2023 | finance.yahoo.com

NEJM Evidence publishes results from Phase I/IIa CYPIDES trial with ODM-208

December 4, 2023 | finance.yahoo.com

87 000 Orion Corporation A shares converted into B shares

November 21, 2023 | finance.yahoo.com

Phase 3 Clinical Trials with ODM-208 (MK-5684) posted to ClinicalTrials.gov database

November 20, 2023 | finance.yahoo.com

Orion Animal Health receives FDA approval for Bonqat® (pregabalin oral solution)

November 15, 2023 | finance.yahoo.com

Orion Research Foundation grants EUR 1,112,000 for research in 2024

November 10, 2023 | morningstar.com

Orion Oyj Class B ORNBV

See More Headlines

Receive ORINY Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Orion Oyj and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 2/13/2024
Today: 4/19/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: OTCMKTS
Sector: Medical
Industry: Private households
Sub-Industry: N/A
Current Symbol: OTCMKTS:ORINY
Previous Symbol: NASDAQ:ORINY
CUSIP: N/A
CIK: N/A
Web: www.orion.fi
Phone: 358 10 4261
Fax: N/A
Employees: 3,527
Year Founded: N/A

Profitability

EPS (Most Recent Fiscal Year): $0.84
Trailing P/E Ratio: 21.43
Forward P/E Ratio: 20.22
P/E Growth: N/A
Net Income: $234.62 million
Net Margins: 18.21%
Pretax Margin: 19.55%
Return on Equity: 27.75%
Return on Assets: 16.32%

Debt

Debt-to-Equity Ratio: 0.21
Current Ratio: 3.10
Quick Ratio: 1.59

Sales & Book Value

Annual Sales: $1.29 billion
Price / Sales: 3.95
Cash Flow: $1.48 per share
Price / Cash Flow: 12.15
Book Value: $3.39 per share
Price / Book: 5.31

Miscellaneous

Outstanding Shares: 282,270,000
Free Float: N/A
Market Cap: $5.08 billion
Optionable: Not Optionable
Beta: 0.23

20 Stocks to Sell Now

MarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.

Get This Free Report

Key Executives

Dr. Liisa Hurme (Age 57)
President, CEO & Chairman of Executive Management Board
Comp: $834.35k
Mr. Jari Karlson M.Sc. (Age 63)
M.Sc. (Econ.), CFO & Member of the Executive Management Board
Mr. Olli Huotari Ll.M. (Age 58)
Senior VP of Corporate Functions, General Counsel, Secretary & Member of Executive Management Board
Ms. Satu Ahomäki M.Sc. (Age 58)
M.Sc. (Econ.), Senior VP of Generics and Consumer Health Business Division & Member of the Exe. Mgmt. Board
Ms. Virve Laitinen M.Sc. (Tech.) (Age 52)
MBA, Sr. VP of Corporate Strategy and Program Mgmt. Grp. Level Function & Member of the Exe. Mgmt. Board
Prof. Outi Vaarala M.D. (Age 62)
Ph.D., Sr. VP of Innovative Medicines, Sr. VP of R&D and Member of the Exe. Mgmt. Board
Mr. Juhani Kankaanpaa
Senior VP of Global Operations & Member of Executive Management Board
Mr. Niclas Lindstedt EMBA
M.Sc., Senior VP of Animal Health Business Division & Member of the Exe. Mgmt. Board
Mr. Hao Pan M.Sc. (Age 53)
Senior VP of the Branded Products Business Division & Member of the Exe. Mgmt. Board
Ms. Julia Irene Macharey (Age 47)
Senior Vice President of People & Culture and Member of Management Board

Key Competitors

View All Competitors

ORINY Stock Analysis - Frequently Asked Questions

Should I buy or sell Orion Oyj stock right now?: 1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Orion Oyj in the last twelve months. There are currently 1 hold rating for the stock. The consensus among Wall Street research analysts is that investors should "hold" ORINY shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in ORINY, but not buy additional shares or sell existing shares.
View ORINY analyst ratings or view top-rated stocks.
How have ORINY shares performed in 2024?: Orion Oyj's stock was trading at $20.70 at the beginning of the year. Since then, ORINY stock has decreased by 13.0% and is now trading at $18.00.
View the best growth stocks for 2024 here.
Are investors shorting Orion Oyj?: Orion Oyj saw a decrease in short interest in the month of March. As of March 15th, there was short interest totaling 100 shares, a decrease of 50.0% from the February 29th total of 200 shares. Based on an average trading volume of 200 shares, the short-interest ratio is currently 0.5 days.
View Orion Oyj's Short Interest.
How were Orion Oyj's earnings last quarter?: Orion Oyj (OTCMKTS:ORINY) announced its quarterly earnings results on Tuesday, February, 13th. The company reported $0.29 earnings per share (EPS) for the quarter. The firm had revenue of $345.76 million for the quarter. Orion Oyj had a net margin of 18.21% and a trailing twelve-month return on equity of 27.75%.

Is Orion Oyj a good dividend stock?: Orion Oyj (OTCMKTS:ORINY) pays an annual dividend of $0.37 per share and currently has a dividend yield of 2.05%. The dividend payout ratio is 44.05%. This payout ratio is at a healthy, sustainable level, below 75%. Based on earnings estimates, ORINY will have a dividend payout ratio of 36.27% next year. This indicates that the company will be able to sustain or increase its dividend.
Read our dividend analysis for ORINY.
How do I buy shares of Orion Oyj?: Shares of ORINY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (OTCMKTS:ORINY) was last updated on 4/19/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial